CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriatic Arthritis" report to their offering.
Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches.
Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors.
The rate of this erosion is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.
Key Topics Covered:
1. Executive Summary
- US
- Inflectra carries biosimilar labeling designation, but is not interchangeable
- Physicians hesitant to use biosimilars, but understand that payers may hold sway
2. Five Major EU Markets
- Insights and strategic recommendations
- Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
- Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
- Payers use biosimilars to pressure originators on pricing
- Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
- Biosimilars will be used as price benchmarks for pipeline agents
- Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
3. Methodology
For more information about this report visit http://www.researchandmarkets.com/research/bczl5n/biosimilars
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biosimilars and Biosuperiors
